Aclaris Therapeutics
A clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases.
The USA-based company is focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under-served immuno-inflammatory conditions.
The company's proprietary KINect technology platform is used to generate clinical candidates for difficult to drug kinases with novel approaches.
Latest Aclaris Therapeutics News & Features
16 January 2024
14 November 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze